NIAID plays a leading role in the discovery, development, and characterization of new vaccine adjuvants that may be used to: improve the efficacy of current vaccines; design new or improved vaccines for existing and emerging infectious diseases; and develop vaccines to treat allergies, autoimmune diseases, and cancer.
Areas of Adjuvant Research
Adjuvant Discovery and Mechanistic Research
Discovery and Mechanistic Research seeks to identify novel adjuvant candidates that can be used to augment the efficacy of human vaccines and elucidate the immune mechanism of novel receptors.
Adjuvant Comparison
Adjuvant Comparison programs support the side-by-side comparison of experimental vaccines formulated with different adjuvants, to include comprehensive assessments of the strength, quality, breadth, and durability of immune responses.
Adjuvant Development
Adjuvant Development supports the preclinical development of novel adjuvants for use in vaccines targeting immune-mediated or infectious diseases.
Clinical Evaluation
This program is intended to address the limited availability of adjuvants that mimic those with a favorable clinical track record or show high potential in late pre-clinical testing.
Additional Resources
Contact Information
Email - DAITAdjuvantGrp@mail.nih.gov
Points of contact for each program can be found on individual program pages.